Market Overview

Morgan Stanley Reiterates Equal-Weight Rating on Abbott Laboratories

Share:
Related ABT
Top Performing Industries For June 16, 2015
Mylan Offers Response to Abbott's Support for Perrigo Deal
FDA clears upstart Theranos' test system (Seeking Alpha)

In a report published Monday, Morgan Stanley reiterated its Equal-Weight rating on Abbott Laboratories (NYSE: ABT).

Morgan Stanley noted, “The critical debates on the new Abbott are: (i) feasibility of upper-single-digit growth, (ii) magnitude of operating leverage and visibility of double-digit earnings growth and (iii) whether a valuation inefficiency exists. We believe Abbott has set expectations at a fair level and is likely to hit targets for mid- to high-single-digit revenue and 10%+ EPS growth.”

Abbott Laboratories closed on Friday at $65.53.

Latest Ratings for ABT

DateFirmActionFromTo
Jun 2015BTIG ResearchInitiates Coverage onBuy
May 2015Evercore PartnersInitiates Coverage onBuy
May 2015Evercore ISIInitiates Coverage onBuy

View More Analyst Ratings for ABT
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Reiteration Analyst Ratings

 

Related Articles (ABT)

Around the Web, We're Loving...

Get Benzinga's Newsletters